Sugammadex, neostigmine and postoperative pulmonary complications (SNaPP): a randomised controlled trial
- Conditions
- Pulmonary atelectasisPneumoniaAcute respiratory distress syndromePulmonary aspirationAnaesthesiology - AnaestheticsSurgery - Other surgeryRespiratory - Other respiratory disorders / diseases
- Registration Number
- ACTRN12623000394640
- Lead Sponsor
- niversity of Melbourne
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 3500
1. Plan for elective or expedited intraabdominal, retroperitoneal, pelvic and non-cardiac intrathoracic surgery
2. Plan for relaxant general anaesthesia with an endotracheal tube
3. Surgery expected to last greater than or equal to 2 hours
4.Expected hospital stay of greater than or equal to 1 postoperative night
1. Unable to provide written informed consent (e.g., language barrier, intellectual disability, cognitive deficit, urgent surgery)
2. Plan for skin incision and/or vascular access at or below the inguinal ligament without an abdominal or thoracic skin incision
3. Plan for intraoperative administration of neuromuscular blocking drug other than rocuronium and vecuronium
4. Plan to reverse neuromuscular blockade during surgery
5. Plan to allow spontaneous complete recovery from neuromuscular blockade during surgery
6. Contraindication to sugammadex or neostigmine
7. Plan for elective postoperative invasive ventilation
8. Previously randomised to the trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of a composite of death from all causes and new pulmonary complications as assessed by trial coordinators from patient history and medical record review during postoperative visits [ From admission to post anaesthesia care unit until hospital discharge (or postoperative day 7 if still in hospital) ]
- Secondary Outcome Measures
Name Time Method